VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Choueiri on Significance of CheckMate-025 Study for RCC

Toni K. Choueiri, MD
Published: Friday, Jan 08, 2016



Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 study in renal cell carcinoma (RCC).

The phase III study compared the efficacy of everolimus, the standard of care, versus nivolumab in patients with metastatic RCC who had received at least one VEGF inhibitor. Results showed that there was a significant survival benefit with nivolumab versus everolimus This led to the drug’s FDA approval.

In subgroup analyses of the study, it was concluded that nivolumab demonstrated improved survival over everolimus in all subgroups, including in poor-risk patients.

<<< View more from the 2016 GU Cancer Symposium



Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 study in renal cell carcinoma (RCC).

The phase III study compared the efficacy of everolimus, the standard of care, versus nivolumab in patients with metastatic RCC who had received at least one VEGF inhibitor. Results showed that there was a significant survival benefit with nivolumab versus everolimus This led to the drug’s FDA approval.

In subgroup analyses of the study, it was concluded that nivolumab demonstrated improved survival over everolimus in all subgroups, including in poor-risk patients.

<<< View more from the 2016 GU Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x